For example, TTI-621 exhibited minimal impact on human erythrocytes, resulting in a lower incidence of anemia than that reported in a phase I study of combinatory treatment of humanized anti-CD47 antibody and rituximab (13% vs 41%) (124, 135). This evidence concerns the gene CD47 and anemia (phenotype).